$32.98+0.23 (+0.70%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Castle Biosciences (CSTL) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~38.3%/yr (FY21→FY25), net margin −7.0%. Worth your attention in FY25: Share count (+15.3%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲3.7%
344.2
FY21→FY25CAGR +38.3%/yr
Net income ($M)—
−24.2
one-off year: see footnoteCAGR —
Free cash flow ($M)▼22.5%
28.3
FY21→FY25CAGR —
Diluted EPS—
−0.83
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+15.3%
25.1mn → 29.0mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$36.0M
+27.2% YoY in FY25 · 10.5% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-7¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 83.2% → 79.4%. Net margin -7.0% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 377,126.0 | 344,229.0 | 332,069.0 | 219,788.0 | 137,039.0 | 94,085.0 | ▲3.7% | +38.3% |
Cost of revenue | 86,467.0 | 71,028.0 | 60,205.0 | 44,982.0 | 32,009.0 | 15,822.0 | ▲18.0% | +45.6% |
Gross profit | 290,659.0 | 273,201.0 | 271,864.0 | 174,806.0 | 105,030.0 | 78,263.0 | ▲0.5% | +36.7% |
Research & development | 58,293.0 | 51,850.0 | 52,041.0 | 53,618.0 | 44,903.0 | 29,646.0 | ▼0.4% | +15.0% |
Selling, general & admin | 251,544.0 | 229,323.0 | 200,047.0 | 180,152.0 | 143,003.0 | 86,738.0 | ▲14.6% | +27.5% |
Total operating expenses | 318,694.0 | 316,011.0 | 263,194.0 | 242,783.0 | 177,885.0 | 118,342.0 | ▲20.1% | +27.8% |
Operating incomefeeds ROC rank | −28,035.0 | −42,810.0 | 8,670.0 | −67,977.0 | −72,855.0 | −40,079.0 | — | — |
Other income, net | 5,416.0 | 13,296.0 | 12,894.0 | 10,612.0 | 3,951.0 | 67.0 | — | — |
Pretax income | −22,619.0 | −29,514.0 | 21,564.0 | −57,365.0 | −68,904.0 | −40,012.0 | — | — |
Income tax | 395.0 | −5,356.0 | 3,319.0 | 101.0 | −1,766.0 | −8,720.0 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −23,014.0 | −24,158.0 | 18,245.0 | −57,466.0 | −67,138.0 | −31,292.0 | — | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −0.75 | −0.83 | 0.62 | −2.14 | −2.58 | −1.24 | — | — |
Diluted shares (mn) | 30.63 | 28.99 | 29.25 | 26.80 | 26.05 | 25.14 | ▼0.9% | +3.6% |
| Margins | ||||||||
Gross margin71st pct in Healthcare | 77.1% | 79.4% | 81.9% | 79.5% | 76.6% | 83.2% | ▼2.5pp | −3.8pp |
Operating margin | −7.4% | −12.4% | 2.6% | −30.9% | −53.2% | −42.6% | ▼15.0pp | +30.2pp |
Net margin31st pct in Healthcare | −6.1% | −7.0% | 5.5% | −26.1% | −49.0% | −33.3% | ▼12.5pp | +26.2pp |
† TTM = trailing four quarters through 2026-09-30.FY22 effective tax rate was 3% vs a 15% norm for this window, likely a one-time item; see the filing.FY23 effective tax rate was −0% vs a 15% norm for this window, likely a one-time item; see the filing.
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Castle Biosciences' revenue last fiscal year?
Castle Biosciences reported revenue of $344.2M in fiscal 2025, up 3.7% from fiscal 2024.
What was Castle Biosciences' net income?
Castle Biosciences reported net income of −$24.2M in fiscal 2025, a net margin of −7.0%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

